SCYNEXIS (NASDAQ:SCYX – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.01, FiscalAI reports.
SCYNEXIS Price Performance
SCYNEXIS stock traded down $0.54 during midday trading on Thursday, hitting $3.30. 133,699 shares of the stock were exchanged, compared to its average volume of 87,392. SCYNEXIS has a fifty-two week low of $3.28 and a fifty-two week high of $9.12. The stock’s 50-day simple moving average is $4.43 and its 200 day simple moving average is $5.49.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on SCYX shares. Weiss Ratings restated a “sell (d-)” rating on shares of SCYNEXIS in a report on Thursday, October 22nd. Brookline Capital Markets reaffirmed a “buy” rating on shares of SCYNEXIS in a report on Friday, July 31st. Wall Street Zen raised SCYNEXIS from a “strong sell” rating to a “hold” rating in a report on Sunday, August 16th. Finally, Guggenheim reiterated a “buy” rating and set a $33.00 price objective (up from $24.00) on shares of SCYNEXIS in a research report on Thursday, August 13th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $33.00.
About SCYNEXIS
SCYNEXIS, Inc is a biotechnology company focused on developing and commercializing innovative antifungal therapies for the treatment of serious and common fungal infections. The company’s research platform is centered on ibrexafungerp, a novel triterpenoid antifungal designed to inhibit glucan synthase, an enzyme important to the formation of fungal cell walls.
SCYNEXIS’s lead product, BREXAFEMME (ibrexafungerp tablets), is an oral antifungal approved in the United States for the treatment of vaginal yeast infections, also known as vulvovaginal candidiasis.
Read More
- Five stocks we like better than SCYNEXIS
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.
